Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Open in API
Filings indexed 962 across all filing types
Latest filing 2021-06-14 Board/Management Inform…
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Board/Management Information 2021
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content is the resignation of a Chief Medical Officer and Chief Scientific Officer, which is a change in senior management. The relevant section is Item 5.02, which deals with departure and appointment of directors or officers. The document does not contain financial statements or detailed financial data, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement or certification. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 3054 characters, which is consistent with a typical 8-K filing for management changes.
2021-06-14 English
Regulatory Filings 2021
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement of a report. Due to the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The document length is sufficient to exclude it being a mere announcement or certification, but the content is unreadable and does not allow for more precise classification.
2021-06-03 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 28, 2021, reporting the entry into a material definitive agreement related to an Open Market Sale Agreement for up to $50 million of common stock. The content focuses on a financing activity, describing the terms of the sale agreement, the agent involved, and the intended use of proceeds. There are no financial statements or detailed financial results presented, so it is not an earnings release or financial report. The document is clearly an update on capital raising activities, fitting the Capital/Financing Update category. The length is 5650 characters, which is sufficient for a substantive filing rather than a brief announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-05-28 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for public offering under the Securities Act of 1933. It includes detailed information about the securities to be offered, the registration fee, and the terms of the offering. This type of filing is related to capital raising activities and financing updates rather than financial performance reports, management changes, or other categories. Therefore, it fits the Capital/Financing Update category (CAP). The document length and content confirm it is not a brief announcement or a report publication notice but the actual registration statement filing.
2021-05-28 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 27, 2021, reporting the results of the 2021 Annual Meeting of Stockholders. It details the voting results on three proposals: election of Class II directors, approval of an amendment to increase authorized shares, and ratification of the appointment of the independent registered public accounting firm. The document contains official voting results from the shareholder meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting. The document is not an Annual Report, Audit Report, or Management Report, nor is it a Proxy Solicitation or Presentation. It is a formal announcement of voting outcomes from the AGM. The document length (5741 characters) and content confirm it is not merely a report publication announcement or a regulatory filing. Therefore, the correct classification is DVA with high confidence.
2021-05-28 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-05-12 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.